Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHA:600671)
China
· Delayed Price · Currency is CNY 19.64
+0.16 (0.82%)
Apr 29, 2026, 3:00 PM CST
SHA:600671 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 211.75 | 216.91 | 121.52 | 107.97 | 146.55 | Upgrade
|
| Other Revenue | - | 0.39 | 0.26 | 0.94 | 0.52 | Upgrade
|
| Revenue | 211.75 | 217.3 | 121.78 | 108.91 | 147.07 | Upgrade
|
| Revenue Growth (YoY) | -2.55% | 78.44% | 11.82% | -25.95% | -28.82% | Upgrade
|
| Cost of Revenue | 110.61 | 116.62 | 98.37 | 93.74 | 106.45 | Upgrade
|
| Gross Profit | 101.14 | 100.68 | 23.41 | 15.16 | 40.62 | Upgrade
|
| Selling, General & Admin | 81.85 | 65.84 | 47.37 | 51.52 | 63.18 | Upgrade
|
| Research & Development | - | 1.21 | 0.48 | 1.58 | 1.33 | Upgrade
|
| Other Operating Expenses | 2.12 | 1.9 | 1.05 | 0.95 | 1.25 | Upgrade
|
| Operating Expenses | 83.97 | 71.24 | 45.91 | 59.05 | 69.81 | Upgrade
|
| Operating Income | 17.17 | 29.44 | -22.5 | -43.89 | -29.19 | Upgrade
|
| Interest Expense | - | -5.56 | -7.19 | -7.4 | -7.35 | Upgrade
|
| Interest & Investment Income | 1.71 | 0.48 | 0.11 | 1.02 | 0.1 | Upgrade
|
| Other Non Operating Income (Expenses) | -7.36 | 0.73 | -2.53 | -2.74 | -0.33 | Upgrade
|
| EBT Excluding Unusual Items | 11.51 | 25.09 | -32.1 | -53.01 | -36.78 | Upgrade
|
| Impairment of Goodwill | - | -0.58 | - | -0.53 | -2.92 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -0.53 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.37 | -0.21 | 0.15 | -0.09 | 0.04 | Upgrade
|
| Asset Writedown | -1.66 | - | -6.01 | -17.24 | - | Upgrade
|
| Other Unusual Items | - | 4.78 | 2.18 | -1.5 | 5.92 | Upgrade
|
| Pretax Income | 10.22 | 29.07 | -36.31 | -72.37 | -33.73 | Upgrade
|
| Income Tax Expense | 3.02 | 7.21 | 2.99 | 0.76 | -0.95 | Upgrade
|
| Earnings From Continuing Operations | 7.2 | 21.87 | -39.3 | -73.12 | -32.78 | Upgrade
|
| Minority Interest in Earnings | 10.42 | -6.62 | 1.02 | 5.61 | 2.98 | Upgrade
|
| Net Income | 17.62 | 15.25 | -38.28 | -67.52 | -29.8 | Upgrade
|
| Net Income to Common | 17.62 | 15.25 | -38.28 | -67.52 | -29.8 | Upgrade
|
| Net Income Growth | 15.59% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 122 | 122 | 122 | 122 | 124 | Upgrade
|
| Shares Outstanding (Diluted) | 122 | 122 | 122 | 122 | 124 | Upgrade
|
| Shares Change (YoY) | 0.01% | -0.01% | -0.00% | -1.92% | 1.13% | Upgrade
|
| EPS (Basic) | 0.14 | 0.13 | -0.31 | -0.55 | -0.24 | Upgrade
|
| EPS (Diluted) | 0.14 | 0.13 | -0.31 | -0.55 | -0.24 | Upgrade
|
| EPS Growth | 15.57% | - | - | - | - | Upgrade
|
| Free Cash Flow | -19.39 | -57.23 | -29.38 | -22.89 | -31.13 | Upgrade
|
| Free Cash Flow Per Share | -0.16 | -0.47 | -0.24 | -0.19 | -0.25 | Upgrade
|
| Gross Margin | 47.76% | 46.33% | 19.23% | 13.92% | 27.62% | Upgrade
|
| Operating Margin | 8.11% | 13.55% | -18.48% | -40.30% | -19.85% | Upgrade
|
| Profit Margin | 8.32% | 7.02% | -31.43% | -62.00% | -20.26% | Upgrade
|
| Free Cash Flow Margin | -9.16% | -26.34% | -24.13% | -21.02% | -21.17% | Upgrade
|
| EBITDA | 31.63 | 41.29 | -11.34 | -29.02 | -19.56 | Upgrade
|
| EBITDA Margin | 14.94% | 19.00% | -9.31% | -26.65% | -13.30% | Upgrade
|
| D&A For EBITDA | 14.46 | 11.85 | 11.16 | 14.86 | 9.64 | Upgrade
|
| EBIT | 17.17 | 29.44 | -22.5 | -43.89 | -29.19 | Upgrade
|
| EBIT Margin | 8.11% | 13.55% | -18.48% | -40.30% | -19.85% | Upgrade
|
| Effective Tax Rate | 29.55% | 24.79% | - | - | - | Upgrade
|
| Revenue as Reported | - | 217.3 | 121.78 | 108.91 | 147.07 | Upgrade
|
| Advertising Expenses | - | 1.19 | 0.9 | 0.77 | 0.46 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.